Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Rituximab 193Cyclophosphamide 177fludarabine phosphate 151Peripheral Blood Stem Cell Transplantation 89fludarabine 77Mycophenolic Acid 70Filgrastim 63Whole-Body Irradiation 59Tacrolimus 55Lenalidomide 54Cyclosporine 54ibrutinib 53Bendamustine Hydrochloride 50Busulfan 49Melphalan 45Radiotherapy 42Etoposide 42Alemtuzumab 42Antilymphocyte Serum 40ofatumumab 35obinutuzumab 33Methotrexate 33venetoclax 27Cytarabine 25sargramostim 23Granulocyte Colony-Stimulating Factor 22Dexamethasone 21Methylprednisolone 19Bortezomib 19Chlorambucil 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Pyrimethamine × Clear all
NCT01066663 2023-02-22

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡